Frances Oldham Kelsey CM
Born	Frances Kathleen Oldham July 24, 1914 Cobble Hill, British Columbia, Canada
Died	August 7, 2015 (aged 101) London, Ontario, Canada
Citizenship	Canada United States (from 1950s)
Alma mater	Victoria College, British Columbia McGill University (BSc, MSc) University of Chicago (PhD, MD)
Occupation	Pharmacologist
Known for	Preventing thalidomide from being marketed in the United States
Spouse	Fremont Ellis Kelsey ​ ​ (m. 1943; died 1966)​
Children	2
Medical career
Field	Physician
Awards	President’s Award for Distinguished Federal Civilian Service (1962)

Frances Kathleen Oldham Kelsey CM (née Oldham; July 24, 1914 – August 7, 2015) was a Canadian-American^[1] pharmacologist and physician. As a reviewer for the U.S. Food and Drug Administration (FDA), she refused to authorize thalidomide for market because she had concerns about the lack of evidence regarding the drug’s safety.^[2] Her concerns proved to be justified when it was shown that thalidomide caused serious birth defects. Kelsey’s career intersected with the passage of laws strengthening FDA oversight of pharmaceuticals. Kelsey was the second woman to receive the President’s Award for Distinguished Federal Civilian Service, awarded to her by John F. Kennedy in 1962.

Birth and education[edit]

Born in Cobble Hill, British Columbia,^[3] Kelsey attended St. Margaret’s School from 1928 to 1931 in the provincial capital, graduating at age 15.^[4] From 1930 to 1931, she attended Victoria College (now University of Victoria). She then enrolled at McGill University, where she received both a B.Sc. (1934) and an M.Sc. (1935) in pharmacology.^[3] Encouraged by one of her professors, she “wrote to EMK Geiling, M.D., a noted researcher [who] was starting up a new pharmacology department at the University of Chicago, asking for a position doing graduate work”.^[4] Geiling, unaware of spelling conventions with respect to Francis and Frances, presumed that Frances was a man and offered her the position, which she accepted, starting work in 1936.^[5][6]

During Kelsey’s second year, Geiling was retained by the FDA to research unusual deaths related to elixir sulfanilamide, a sulfonamide medicine. Kelsey assisted on this research project, which showed that the 107 deaths were caused by the use of diethylene glycol as a solvent. The next year, the United States Congress passed the Federal Food, Drug, and Cosmetic Act of 1938.^[4] That same year she completed her studies and received a Ph.D. in pharmacology at the University of Chicago.^[4] Working with Geiling led to her interest in teratogens, drugs that cause congenital malformations (birth defects).^[7]

Early career[edit]

Upon completing her Ph.D., Oldham joined the University of Chicago faculty. In 1942, like many other pharmacologists, Oldham was looking for a synthetic cure for malaria. As a result of these studies, Oldham learned that some drugs are able to pass through the placental barrier.^[8] During her work, she also met fellow faculty member Fremont Ellis Kelsey, whom she married in 1943.^[4]

While on the faculty at the University of Chicago, Kelsey was awarded her M.D. in 1950.^[4] She supplemented her teaching with work as an editorial associate for the American Medical Association Journal for two years. Kelsey left the University of Chicago in 1954, decided to take a position teaching pharmacology at the University of South Dakota, and moved with her husband and two daughters to Vermillion, South Dakota, where she taught until 1957.^[3]

She became a dual citizen of Canada and the United States in the 1950s in order to continue practicing medicine in the U.S., but retained strong ties to Canada where she continued to visit her siblings regularly until late in life.^[2]

Work at the FDA and thalidomide[edit]

In 1960, Kelsey was hired by the FDA in Washington, D.C. At that time, she “was one of only seven full-time and four young part-time physicians reviewing drugs”^[4] for the FDA. One of her first assignments at the FDA was to review an application by Richardson-Merrell for the drug thalidomide (under the tradename Kevadon) as a tranquilizer and painkiller with specific indications to prescribe the drug to pregnant women for morning sickness. Although it had been previously approved in Canada and more than 20 European and African countries,^[9] she withheld approval for the drug and requested further studies.^[3] Despite pressure from thalidomide’s manufacturer Grünenthal, Kelsey persisted in requesting additional information to explain observations by Leslie Florence of neurological symptoms published in the British Medical Journal in December 1960.^[4][10] She also requested data showing the drug was not harmful to the fetus.^[10]

Kelsey’s insistence that the drug should be fully tested prior to approval was vindicated when the births of deformed infants in Europe were linked to thalidomide ingestion by their mothers during pregnancy.^[11][12] Researchers discovered that the thalidomide crossed the placental barrier and caused serious birth defects.^[8] She was hailed on the front page of The Washington Post as a heroine^[13] for averting a similar tragedy in the U.S.^[14] Morton Mintz, author of The Washington Post article, said “[Kelsey] prevented … the birth of hundreds or indeed thousands of armless and legless children.”^[13] Kelsey insisted that her assistants, Oyama Jiro and Lee Geismar, as well as her FDA superiors who backed her strong stance, deserved credit as well. The narrative of Kelsey’s persistence was used to help pass rigorous drug approval regulation in 1962.^[1]

After Mintz broke the story in July 1962, there was a substantial public outcry. The Kefauver Harris Amendment was passed unanimously by Congress in October 1962 to strengthen drug regulation.^[11][12] Companies were required to demonstrate the efficacy of new drugs, report adverse reactions to the FDA, and request consent from patients participating in clinical studies.^[15] The drug testing reforms required “stricter limits on the testing and distribution of new drugs”^[8] to avoid similar problems. The amendments, for the first time, also recognized that “effectiveness [should be] required to be established prior to marketing.”^[11][12]

As a result of her blocking American approval of thalidomide, Kelsey was awarded the President’s Award for Distinguished Federal Civilian Service by John F. Kennedy on August 7, 1962,^[16] becoming the second woman so honoured.^[17] After receiving the award, Kelsey continued her work at the FDA. There, she played a key role in shaping and enforcing the 1962 amendments.^[14] She also became responsible for directing the surveillance of drug testing at the FDA.^[3]

Kelsey retired from the FDA in 2005, at age 90, after 45 years of service.^[9] In 2010, the FDA named the Kelsey Award for her, to be awarded annually to an FDA employee for “Excellence and Courage in Protecting Public Health”.^[18]

Later life and death[edit]

Kelsey continued to work for the FDA while being recognised for her earlier work. She was still working at the FDA’s Center for Drug Evaluation and Research in 1995 and was appointed deputy for scientific and medical affairs. In 1994, the Frances Kelsey Secondary School in Mill Bay, British Columbia, was named in her honour.^[19]

In 2010, the FDA presented Kelsey with the first Drug Safety Excellence Award and named the annual award after her,^[20] announcing that it would be given to one FDA staff member annually.^[21] In announcing the awards, Center Director Steven K. Galson said: “I am very pleased to have established the Dr. Frances O. Kelsey Drug Safety Excellence Award and to recognize the first recipients for their outstanding accomplishments in this important aspect of drug regulation.”^[22]

Kelsey turned 100 in July 2014,^[23] and shortly thereafter, in the fall of 2014, she moved from Washington, D.C., to live with her daughter in London, Ontario.^[24] In June 2015, when she was named to the Order of Canada, Mercédes Benegbi, a thalidomide victim and the head of the Thalidomide Victims Association of Canada, praised Kelsey for showing strength and courage by refusing to bend to pressure from drug company officials, and said “To us, she was always our heroine, even if what she did was in another country.”^[24]

Kelsey died in London, Ontario, on August 7, 2015, at the age of 101,^[25] less than 24 hours after Ontario’s Lieutenant-Governor, Elizabeth Dowdeswell, visited her home to present her with the insignia of Member of the Order of Canada for her role against thalidomide.^[26]

Legacy and awards[edit]

• 1962 • President’s Award for Distinguished Federal Civilian Service^[9]
• 1963 • Gold Key Award from University of Chicago, Medical and Biological Sciences Alumni Association^[27]
• 1994 • Chosen as the namesake for Frances Kelsey Secondary School which opened in 1995.
• 2000 • Inducted into the National Women’s Hall of Fame^[17]
• 2001 • Named a Virtual Mentor for the American Medical Association^[28]
• 2006 • Foremother Award from the National Center for Health Research^[29]
• 2010 • Recipient of the first Dr. Frances O. Kelsey Award for Excellence and Courage in Protecting Public Health given out by the FDA^[30]
• 2012 • Honorary doctor of science degree from Vancouver Island University^[31]
• 2015 • Named to the Order of Canada^[24]

See also[edit]

• European Medicines Agency

References[edit]

Further reading[edit]

Wikimedia Commons has media related to Frances Oldham Kelsey.

• Bren, Linda (March–April 2001), “Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on History”, FDA Consumer, 35 (2): 24–29, PMID 11444245, archived from the original on October 20, 2006, retrieved August 15, 2009
• Harris, Gardiner (September 13, 2010), “The Public’s Quiet Savior From Harmful Medicines”, The New York Times.
• Harris, Steven B. (1992), The Right Lesson to Learn from Thalidomide, archived from the original on April 20, 2001.
• Kelsey, Frances O. (1993), Autobiographical Reflections (PDF). This was drawn from oral history interviews conducted in 1974, 1991, and 1992; presentation, Founder’s Day, St. Margaret’s School, Duncan, B. C., 1987; and presentation, groundbreaking, Frances Kelsey School, Mill Bay, B. C., 1993.
• McGovern, James (2020), “Quieter Things: The Tale of Frances Oldham Kelsey”, Boulevard, 35 (2 & 3): 209–219.
• Mintz, Morton (1965), The therapeutic nightmare; a report on the roles of the United States Food and Drug Administration, the American Medical Association, pharmaceutical manufacturers, and others in connection with the irrational and massive use of prescription drugs that may be worthless, injurious, or even lethal., Boston: Houghton Mifflin, LCCN 65015156. Library of Congress catalog entry.
• McFadyen, R. E. (1976), “Thalidomide in America: A Brush With Tragedy”, Clio Medica, 11 (2): 79–93, PMID 61093.
• Mulliken, J. (August 10, 1962), “A Woman Doctor Who Would Not be Hurried”, Life, vol. 53, pp. 28–9, LCCN 37008367.
• Perri III, Anthony J.; Hsu MD, Sylvia (2003), “A review of thalidomide’s history and current dermatological applications”, Dermatology Online Journal, 9 (3): 5, doi:10.5070/D35FK5W0QV, PMID 12952752, retrieved August 14, 2006.
• Seidman, Lisa A.; Warren, Noreen (September 2002), “Frances Kelsey & Thalidomide in the US: A Case Study Relating to Pharmaceutical Regulations” (PDF), The American Biology Teacher, 64 (7): 495, doi:10.1662/0002-7685(2002)064[0495:FKTITU]2.0.CO;2, 7.
• Stamato, Linda (December 17, 2012), “Thalidomide, after fifty years: A tribute to Frances Oldham Kelsey and a call for thorough, responsible federal drug regulation and oversight”, NJ Voices.